Market Performance Overview
The shares of Heron Therapeutics Inc. (NASDAQ: HRTX) experienced a notable decline of –11.76 % during the 24‑hour trading window that closed at 11:09 AM Central Europe on Friday, 23 September 2026. At the close, one share was valued at approximately USD 0.30 on major exchanges. With a circulating supply of 189.9 million shares, the company’s market capitalization settled at USD 63.8 million. In the preceding day, the stock traded in total volume of roughly USD 1.4 million, indicating a moderate level of liquidity.
When viewed in a broader temporal context, HRTX’s share price has risen by 3.45 % since the end of last month. Its 200‑day simple moving average currently sits at USD 0.73, while the peak price recorded over the past 52 weeks was USD 1.58 on 1 September 2026. Conversely, the lowest price in the same period was USD 0.26 on 21 September 2026.
Comparative Performance of Peer Companies
A snapshot of related biotech equities in the past 24 hours illustrates a mixed performance landscape:
| Symbol | Recent Change | Current Price (USD) | Market Cap (USD mn) |
|---|---|---|---|
| FATN (Fatpipe / Ut) | 0 % | 5.31 | 75.5 |
| NDLS (Noodles &) | –5.03 % | 11.90 | 74.8 |
| CSPI (Csp) | –1.47 % | 7.37 | 75.4 |
| TELO (Telomir) | +0.99 % | 1.01 | 75.1 |
| OM (Outset Medical) | –4.03 % | 4.17 | 76.1 |
These figures underscore the volatility typical of specialty pharmaceutical and biotechnology stocks, where short‑term swings can be driven by a variety of factors, including earnings updates, regulatory decisions, and market sentiment.
Company Profile
Heron Therapeutics Inc. is headquartered in San Diego, California, and operates within the broader Health Care sector. The company has developed a proprietary biochronomer drug‑delivery platform that aims to enhance the therapeutic efficacy of injectable pharmaceuticals by improving their pharmacokinetic profiles. In addition to its core technology, Heron focuses on identifying existing therapies that could be reformulated to take advantage of its delivery system.
The firm was initially publicized with an IPO on 26 August 1987 and remains listed on the NASDAQ exchange. Further details regarding its product pipeline and corporate strategy are available on its website at www.herontx.com .
This article provides an objective overview of Heron Therapeutics’ recent market activity, contextualizes its performance among peer firms, and summarizes key company attributes for investors and market observers.
